Portia Ku

Partner

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Portia Ku is an accomplished corporate transactional lawyer who specializes in capital markets, mergers and acquisitions, venture capital and private equity financings. Portia’s clients include public and private companies that span a variety of industries, including the technology, life sciences, healthcare, and financial services sectors.

Portia has successfully completed a myriad of deals on behalf of her clients. She applies her expansive technical experience, strategic execution, and dedication to guide clients through highly complex transactions while ultimately helping them achieve their corporate goals.

Languages

  • Mandarin Chinese
  • Taiwanese

Honors & Awards

  • Recognized as a "Leading Lawyer" (2017)  and "Highly Regarded" (2018-2020) in Capital Markets and Private Equity by IFLR1000

Admissions

Bar Admissions

  • California
  • New York
  • Taiwan

Education

  • Yale University, LL.M.
  • National Taiwan University, LL.B.

Professional Activities

Speaking Engagements

  • “Fundraising from the International Biotech Industry - Looking for Opportunities in Taiwan," Taiwan National Biotechnology Research Park (June 12, 2020)

IPO Experience (companies):

  • Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
  • eHi Car Services (NYSE: EHIC) in its US$120 million IPO and listing on the NYSE
  • Montage Technology Group Limited (NASDAQ: MONT) in its US$81.7 million IPO and listing on NASDAQ
  • China Kanghui Holdings (NYSE: KH) in its US$78.7 million IPO and listing on the NYSE
  • iSoftStone Holdings Ltd. (NYSE: ISS) in its US$162 million IPO and listing on the NYSE
  • 7 Days Group Holdings (NYSE: SVN) in its US$127.8 million IPO and listing on the NYSE
  • Giant Interactive Group Inc. (NYSE: GA) in its US$1.02 billion IPO and listing on the NYSE
  • WuXi PharmaTech (NYSE: WX) in its US$212 million IPO and listing on the NYSE
  • Acorn International, Inc. (NYSE: ATV) in its US$119.4 million IPO and listing on the NYSE
  • Mindray Medical International Limited (NYSE: MR) in its US$320 million IPO and listing on the NYSE
  • Christine International Holdings Ltd. (1210.HK) in its HK$400 million IPO and listing on the Hong Kong Stock Exchange
  • LifeTech Scientific Corporation (8122.HK) in its HK$283 million IPO on the Growth Enterprise Market of the Hong Kong Stock Exchange
  • Besunyen Holdings Company Limited (0926.HK) in its HK$1.3 billion IPO and listing on the Hong Kong Stock Exchange

IPO Experience (underwriters):

  • Credit Suisse and Deutsche Bank in US$174 million US IPO of Tudou Holding Ltd. (NASDAQ: TUDO)
  • Morgan Stanley and CICC in US$132 million US IPO of Concord Medical Services Holdings (NYSE: CCM)
  • Credit Suisse and Citigroup in US$73 million US IPO of Chemspec International Limited (NYSE: CPC)
  • Merrill Lynch in US$108 million US IPO of China Sunergy Co., Ltd. (NASDAQ: CSUN)
  • the underwriters in the IPO of CNOOC
  • the underwriters in the IPO of Comtech
  • the underwriters in the IPO of TravelSky Technology
  • the underwriters in the IPO of Sohu.com
VIEW MORE